IRIS
GRAGNANO, Felice
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 8.986
AS - Asia 4.756
NA - Nord America 4.071
SA - Sud America 728
AF - Africa 86
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 4
Totale 18.637
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 6.910
US - Stati Uniti d'America 3.968
SG - Singapore 1.687
CN - Cina 987
VN - Vietnam 779
IE - Irlanda 774
HK - Hong Kong 678
BR - Brasile 613
IT - Italia 392
GB - Regno Unito 225
DE - Germania 216
KR - Corea 206
IN - India 158
FR - Francia 102
UA - Ucraina 60
GR - Grecia 54
AR - Argentina 53
AT - Austria 48
BD - Bangladesh 48
CA - Canada 47
FI - Finlandia 44
SE - Svezia 41
JP - Giappone 40
MX - Messico 40
NL - Olanda 28
ID - Indonesia 26
TR - Turchia 25
IQ - Iraq 23
BE - Belgio 22
MA - Marocco 21
CO - Colombia 20
ZA - Sudafrica 16
EG - Egitto 15
ES - Italia 15
PK - Pakistan 15
KE - Kenya 13
PL - Polonia 13
EC - Ecuador 11
SA - Arabia Saudita 11
UZ - Uzbekistan 11
CL - Cile 8
LT - Lituania 8
VE - Venezuela 8
TN - Tunisia 7
IL - Israele 6
JO - Giordania 6
AU - Australia 5
HN - Honduras 5
NP - Nepal 5
PY - Paraguay 5
TH - Thailandia 5
TW - Taiwan 5
AE - Emirati Arabi Uniti 4
CZ - Repubblica Ceca 4
KZ - Kazakistan 4
MY - Malesia 4
NO - Norvegia 4
PE - Perù 4
RS - Serbia 4
UY - Uruguay 4
CH - Svizzera 3
EU - Europa 3
IR - Iran 3
MD - Moldavia 3
PH - Filippine 3
AL - Albania 2
AM - Armenia 2
AZ - Azerbaigian 2
BW - Botswana 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
JM - Giamaica 2
KH - Cambogia 2
RO - Romania 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
AN - Antille olandesi 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CY - Cipro 1
DK - Danimarca 1
EE - Estonia 1
ET - Etiopia 1
GE - Georgia 1
GH - Ghana 1
GY - Guiana 1
HR - Croazia 1
IS - Islanda 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LU - Lussemburgo 1
LV - Lettonia 1
Totale 18.622
Salva come PNG Salva come JPEG
Città #
Moscow 2.595
San Jose 988
Singapore 764
Dublin 760
Hong Kong 664
Santa Clara 663
Chandler 359
Ho Chi Minh City 262
Hefei 246
Ashburn 224
Seoul 198
Hanoi 182
Beijing 138
New York 108
The Dalles 102
Jacksonville 101
Princeton 94
Roxbury 94
Bengaluru 90
Dallas 76
Naples 69
São Paulo 56
Da Nang 55
Nuremberg 53
Los Angeles 50
Cambridge 49
Medford 48
Bremen 44
Falkenstein 35
Des Moines 32
Haiphong 30
Boardman 29
Ann Arbor 26
Caserta 26
Wilmington 24
Brussels 22
Rio de Janeiro 20
Council Bluffs 19
Aversa 18
Lappeenranta 18
Orem 18
Hyderabad 17
Thái Nguyên 17
Biên Hòa 16
Helsinki 16
Munich 16
Rome 16
Frankfurt am Main 15
Mexico City 15
Nanjing 15
Vienna 15
Amsterdam 14
Belo Horizonte 14
Houston 14
Montreal 14
Brooklyn 13
Dhaka 12
Hải Dương 12
San Francisco 12
Tokyo 12
Atlanta 11
Bến Tre 11
Chennai 11
Guangzhou 11
London 11
Milan 11
Nairobi 11
Nha Trang 11
Ninh Bình 11
Tashkent 11
Toronto 11
Boston 10
Brasília 10
Campinas 10
Curitiba 10
Ercolano 10
Hangzhou 10
Napoli 10
Phoenix 10
Porto Alegre 10
Salvador 10
Shenzhen 10
Chicago 9
Jinan 9
Johannesburg 9
Memphis 9
Thái Bình 9
Bogotá 8
Columbus 8
Norwalk 8
Sivas 8
Stockholm 8
Baghdad 7
Cairo 7
Can Tho 7
Hillsboro 7
Lấp Vò 7
Manchester 7
Mumbai 7
Riyadh 7
Totale 10.096
Salva come PNG Salva come JPEG
Nome #
Adiponectin and insulin resistance are related to restenosis and overall new PCI in subjects with normal glucose tolerance: the prospective AIRE Study 221
Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience 182
MicroRNA-33 and SIRT1 influence the coronary thrombus burden in hyperglycemic STEMI patients 166
Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease 164
Cardiorenal Impact of SGLT-2 Inhibitors: A Conceptual Revolution in The Management of Type 2 Diabetes, Heart Failure and Chronic Kidney Disease 163
Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry 161
Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition 159
Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience 158
Natural history of left ventricular hypertrophy in infants of diabetic mothers 157
Antithrombotic therapy in patients with atrial high-rate episodes (AHREs): Current evidence and open questions 156
Adherence to PCSK9 inhibitors in high cardiovascular risk patients in real-world setting: results from a single-center experience and comparison with statin therapy 154
Medical treatment of patients with hypertrophic cardiomyopathy: An overview of current and emerging therapy 152
Access-Site Crossover in Patients With Acute Coronary Syndrome Undergoing Invasive Management 152
New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia 149
[The COMPASS study] 148
[Device therapy in chronic heart failure: a case of hypertrophic cardiomyopathy treated with cardiac contractility modulation therapy] 145
Alcohol Septal Ablation in Patients with Hypertrophic Obstructive Cardiomyopathy: A Contemporary Perspective 144
Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: the emerging role of the Cardiomyopathy Team 143
Acute kidney injury in patients with acute coronary syndrome undergoing invasive management treated with bivalirudin vs. unfractionated heparin: insights from the MATRIX trial 140
Antithrombotic Therapy Optimization in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention 137
Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: A contemporary reappraisal 137
Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry 136
Sodium-Glucose Co-Transporters Family: Current Evidence, Clinical Applications and Perspectives 133
ICARUS score for predicting peri-procedural bleeding in patients undergoing percutaneous coronary intervention with cangrelor 133
Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry) 132
Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry 131
New frontiers in antiplatelet therapy: guided therapy and de-escalation after acute coronary syndrome or percutaneous coronary intervention 130
Anti-inflammatory therapies for cardiovascular diseases: novel evidence, clinical implications, and future perspectives 129
A call for action in bleeding prevention 129
[Evaluation and percutaneous treatment of severely calcified coronary lesions] 129
Coronary Physiology Assessment for the Diagnosis and Treatment of Coronary Artery Disease 128
De-escalation strategies in patients with acute coronary syndrome: a step towards precision medicine 128
[Debate on antiplatelet monotherapy: P2Y12 inhibitor monotherapy in patients with coronary artery disease] 127
Low-Dose Ticagrelor in Patients With High Ischemic Risk and Previous Myocardial Infarction: A Multicenter Prospective Real-World Observational Study 127
A Prospective Study to Evaluate the Effectiveness of Edoxaban for the Resolution of Left Atrial Thrombosis in Patients with Atrial Fibrillation 125
Immune-Checkpoint Inhibitor-Related Myocarditis: Where We Are and Where We Will Go 123
Role of LipoprotEin(a) in CardiovascuLar diseases and premature acute coronary syndromes (RELACS study): Impact of Lipoprotein(a) levels on the premature coronary event and the severity of coronary artery disease 123
Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease 123
Long-Term Antithrombotic Therapy in Patients with Atrial Fibrillation and Percutaneous Coronary Intervention 122
How do cardiologists select patients for dual antiplatelet therapy continuation beyond 1 year after a myocardial infarction? Insights from the EYESHOT Post-MI Study 122
Discrepancies Between Physician-Perceived and Calculated Cardiovascular Risk in Primary Prevention: Implications for LDL-C Target Achievement and Appropriate Lipid-Lowering Therapy 119
Visceral adipose tissue and residual cardiovascular risk: a pathological link and new therapeutic options 118
[Gut microbiota and the cardiovascular system: current evidence and future perspectives] 118
Functional assessment of coronary stenosis: an overview of available techniques. Is quantitative flow ratio a step to the future? 116
Anticoagulation After Primary PCI: The Land of Promises and Uncertainty 116
Thrombus aspiration in hyperglycemic ST-elevation myocardial infarction (STEMI) patients: Clinical outcomes at 1-year follow-up 115
Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry 113
Ticagrelor monotherapy after acute coronary syndrome: lessons from the ULTIMATE-DAPT trial 113
Antithrombotic Therapy after TAVI: Evidence, Discordance, and Clinical Implications 113
2024 ESC guidelines on chronic coronary syndromes: what is new in pharmacotherapy? 112
Mandatory reporting of coronary artery calcifications incidentally noted on chest multi-detector computed tomography: a multicentre experience 111
Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: Insight from SGLT2-I AMI PROTECT registry 109
Von Willebrand Factor as a Novel Player in Valvular Heart Disease: From Bench to Valve Replacement 109
Escalation and De-Escalation of Antiplatelet Therapy after Acute Coronary Syndrome or PCI: Available Evidence and Implications for Practice 108
Thrombus aspiration in hyperglycemic ST-elevation myocardial infarction (STEMI) patients: clinical outcomes at 1-year follow-up (vol 17, pg 512, 2018) 108
Early-onset MINOCA: Prognostic implications and considerations for practice 108
A pragmatic approach for thrombotic prevention after acute coronary syndromes 107
Antithrombotic Therapy in High Bleeding Risk, Part I: Percutaneous Cardiac Interventions 107
Are we ready for a gender-specific approach in interventional cardiology? 106
Inflammation in patients undergoing transcatheter aortic valve implantation: a therapeutic target for the future? 105
Von Willebrand Factor and cardiovascular disease: from a biochemical marker to an attractive therapeutic target 105
Dietary thiols: A potential supporting strategy against oxidative stress in heart failure and muscular damage during sports activity 105
Ticagrelor or Clopidogrel Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Patient-Level Meta-Analysis 104
Improving adherence to Ticagrelor in patients after acute coronary syndrome: Results from the PROGRESS trial 104
In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study 103
Use of bempedoic acid for LDL cholesterol lowering and cardiovascular risk reduction: a consensus document from the Italian study group on atherosclerosis, thrombosis and vascular biology 102
Choice of access site and type of anticoagulant in acute coronary syndromes with advanced Killip class or out-of-hospital cardiac arrest 102
Role of dual lipid-lowering therapy in coronary atherosclerosis regression: Evidence from recent studies 102
P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials 102
Severely calcified coronary artery lesions: focus on interventional management 101
Simulation Models of Therapy Intensification in Lipid-Lowering Medicine: Fact or Fantasy? 101
Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and atrial thrombosis: An appraisal of current evidence 101
Understanding the role of coronary artery revascularization in patients with left ventricular dysfunction and multivessel disease 101
Impact of SGLT2-inhibitors on acute kidney injury in diabetic patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI) 100
Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies 100
The year in cardiovascular pharmacotherapy 2022: landmark evidence at a glance 99
Risk Scores of Bleeding Complications in Patients on Dual Antiplatelet Therapy: How to Optimize Identification of Patients at Risk of Bleeding after Percutaneous Coronary Intervention 99
Echocardiographic monitoring in cancer therapy: clinical guidance for cardiologists and oncologists 99
Gender-related differences in changes of estimated bleeding risk in patients on dual antiplatelet therapy: the RE-SCORE multicenter prospective registry 98
A real-world multicenter study on left atrial appendage occlusion: The Italian multi-device experience 98
Optimizing Management of Stable Angina: A Patient-Centered Approach Integrating Revascularization, Medical Therapy, and Lifestyle Interventions 97
Prevalence and clinical significance of red flags in patients with hypertrophic cardiomyopathy 97
Impact of Clinical Presentation on Bleeding Risk after Percutaneous Coronary Intervention and Implications for the ARC-HBR Definition 97
CYP2C19 Genotyping to Risk Stratify Patients After Coronary Stent Implantation: Time for a Personalized Approach? 96
AZALEA–TIMI 71 trial: less bleeding with abelacimab compared to rivaroxaban in atrial fibrillation, but stroke prevention is uncertain 95
von Willebrand Factor and Venous Thromboembolism: Pathogenic Link and Therapeutic Implications 95
Beyond the left ventricle: Why the right heart matters in Takotsubo syndrome 94
P2Y12 Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary Interventions 93
ECG analysis in patients with acute coronary syndrome undergoing invasive management: rationale and design of the electrocardiography sub-study of the MATRIX trial 93
null 93
Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: Per-Protocol Analysis of the GLOBAL LEADERS Trial 93
The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy 92
Potential role of imaging markers in predicting future disease expression of arrhythmogenic cardiomyopathy 92
P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events 91
Epidemiology and Management of Patients With Acute Coronary Syndromes in Contemporary Real-World Practice: Evolving Trends From the EYESHOT Study to the START-ANTIPLATELET Registry 91
Perioperative care of cardiac patient’s candidate for non-cardiac surgery: a critical appraisal of emergent evidence and international guidelines 91
Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients with ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial 91
SGLT2 Inhibitors as the Backbone of Therapy for Cardiovascular and Renal Protection 90
Long-term antiplatelet monotherapy after PCI: searching for the smart choice 90
Letter by Calabrò et al Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)" 90
Totale 11.836
Salva come PNG Salva come JPEG
Categoria #
all - tutte 66.867
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 66.867
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202128 0 0 0 0 0 0 0 0 0 0 0 28
2021/2022778 10 1 8 28 194 11 12 121 21 93 59 220
2022/20231.332 129 73 32 93 121 72 4 69 672 8 26 33
2023/2024734 44 21 22 37 191 108 54 6 6 33 54 158
2024/20252.890 7 28 8 77 452 383 357 237 403 463 280 195
2025/202612.774 458 679 657 587 954 6.454 917 888 465 405 194 116
Totale 19.162